Zai Lab (HKSE:09688) OCF Margin %: -11.96% (As of Mar. 2026)


HKSE:09688 Zai Lab Ltd HKSE:09688
78 GF Score
Price HK$14.47
GF Value HK$23.85
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab OCF Margin %?

Zai Lab HKSE:09688 +1.97% 78 OCF Margin % is -11.96% as of Mar. 2026. GuruFocus rates HKSE:09688 with a GF Score™ of 78/100 and a GF Value™ of HK$23.85 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 960 Biotechnology companies, Zai Lab ranks better than 58.33% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Zai Lab's Cash Flow from Operations for the three months ended in Mar. 2026 was HK$-93 Mil. Zai Lab's Revenue for the three months ended in Mar. 2026 was HK$780 Mil. Therefore, Zai Lab's OCF Margin % for the quarter that ended in Mar. 2026 was -11.96%.

As of today, Zai Lab's current OCF Yield % is -4.83%.

The historical rank and industry rank for Zai Lab's OCF Margin % or its related term are showing as below:

HKSE:09688' s OCF Margin % Range Over the Past 10 Years
Min: -75610.85   Med: -275.78   Max: -32.77
Current: -22.28


During the past 11 years, the highest OCF Margin % of Zai Lab was -32.77%. The lowest was -75610.85%. And the median was -275.78%.

HKSE:09688's OCF Margin % is ranked better than
58.33% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs HKSE:09688: -22.28


Zai Lab OCF Margin % Related Terms


Zai Lab OCF Margin % Historical Data

* Premium members only.

The historical data trend for Zai Lab's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab OCF Margin % Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -380.59 -170.96 -74.30 -53.85 -32.77

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.94 -28.21 -27.60 -20.39 -11.96

HKSE:09688 vs TYRA, TRVI, OCUL: OCF Margin % Comparison

For the Biotechnology subindustry, Zai Lab's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Zai Lab's OCF Margin % falls into.


HKSE:09688
78GF Score
Zai Lab Ltd HKSE:09688
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Zai Lab's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1173.259/3580.382
=-32.77 %

Zai Lab's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-93.233/779.635
=-11.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -11.96% mean?
Zai Lab (HKSE:09688) has a OCF Margin % of -11.96% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #400 out of 960 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Zai Lab's OCF Margin % too high?
Zai Lab's current OCF Margin % is -11.96%. Based on the distribution chart, Zai Lab ranks #400 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's OCF Margin % compare to TYRA and TRVI?
According to the Biotechnology industry distribution chart, Zai Lab ranks #400 out of 960 companies for OCF Margin %. This puts Zai Lab in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zai Lab and its competitors. Zai Lab's current OCF Margin % is -11.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (HKSE:09688) is currently considered Possible Value Trap. The stock's GF Value™ is HK$23.85, compared to a current price of HK$14.47 — trading 39.3% below its estimated fair value. The current OCF Margin % is -11.96%. Zai Lab's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Zai Lab (HKSE:09688), the current OCF Margin % is -11.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (HKSE:09688) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of HK$14.47 is trading 39.3% below its estimated GF Value™ of HK$23.85. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for HKSE:09688:

  • OCF Margin %: -11.96%
  • GF Value™: HK$23.85 vs. price of HK$14.47 (39.3% below fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the HKSE:09688 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zai Lab Business Description

Other Exchanges ZLAB:USA1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
78GF Score

Get the complete analysis for HKSE:09688

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.47
Price
HK$23.85
GF Value